A review: hemocompatibility of magnetic nanoparticles and their regenerative medicine, cancer therapy, drug delivery, and bioimaging applications

Abstract

Nanoparticles have demonstrated noteworthy advancements in the management of various complex medical conditions, particularly cancer. In any case, these particles still harbor the potential to improve medicate conveyance to challenging, hard-to-reach loci. The interactions that occur between nanoparticles and red blood cells during their journey throughout the human body, despite exposure to blood, are still not fully understood. Assessment of the ability of nanoparticles to integrate with blood, characterized as nanoparticle compatibility, has been consistently overlooked and undervalued in its import. This review article investigates the effect of nanoparticles on red blood cells, while examining the compatibility of nanoparticles through the angle of hemolysis. This article discusses the main roles of erythrocytes and also provides an informed interpretation of several mechanisms involved in the interaction of nanoparticles and erythrocytes. Throughout the review, significant emphasis is attributed to the investigation of hemocompatibility studies concerning newly designed nanoparticles to promote their successful translation into clinical application. This review article examines the compatibility of magnetic nanoparticles in various fields, including regenerative medicine, cancer therapy, bioimaging, and drug delivery. Our results show that the chemical composition of the nanoparticle surface is a determining factor in hemocompatibility performance and interaction with blood cells. The surface properties of nanoparticles, namely surface charge, geometry, porosity, and surface functionalities of polymers or specific functional groups, represent key determinants of hemocompatibility.

ULK1 Mediated Autophagy-Promoting Effects of Rutin-Loaded Chitosan Nanoparticles Contribute to the Activation of NF-κB Signaling Besides Inhibiting EMT in Hep3B Hepatoma Cells

“…In this regard, the percentage of hemolysis at 0–2% is non-hemolytic, whereas 2–5% range exhibit low hemolysis. 264 Since the desired percentage of hemolysis is less than 5%, the rCNPs are safe to use (with non-hemolytic profile) and can be administered intravenously owing to their compatibility with blood. 138 …”

Nanoparticles for efficient drug delivery and drug resistance in glioma: New perspectives

“…For example, nanoliposomes and nanoemulsions have been widely used to deliver anticancer drugs. 166 Some NPs have unique optical, magnetic, and electrical properties that can be used for bioimaging, such as iron oxide NPs for magnetic resonance imaging 167 and carbon nanotubes for optical imaging. 168 There are also NPs that can be used directly to treat diseases, such as gold NPs that can be used to treat cancer by killing cancer cells through heating.…”

The application of peroxidase mimetic nanozymes in cancer diagnosis and therapy

“…Cancer is well recognized as a prominent contributor to human mortality ( Sung et al, 2021 ; Malehmir et al, 2023a ; Jafari et al, 2023 ). The uncontrolled proliferation of malignant cells and their spread to other parts of the human body are linked to a variety of disorders known as cancer ( Keyvani et al, 2022 ; Mohammadi M. et al, 2023 ; Malehmir et al, 2023b ). One of the most significant obstacles in cancer therapy is the recurrence of tumors, the spread of malignancies or metastases, and the development of resistance to chemotherapy treatments ( Bukowski et al, 2020 ; Riggio et al, 2021 ; Hasan-Abad et al, 2022 ; Mohammadi AH.…”